Controversies Regarding Subclinical Leaflet Thrombosis After TAVR
Published: 25 February 2021
10m 22sPart 2 | Session 1 PRO
10m 45sPart 2 | Session 2 CONTRA
13m 38sPart 2 | Session 3 Panel discussion & Audience Questions
11m 47sPart 3 | Session 1 PRO
15m 43sPart 3 | Session 2 CONTRA
11m 57sPart 3 | Session 3 Panel discussion & Audience Questions
A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).
The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.
Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.
- To learn about the natural history, incidence and clinical implications of SLT
- To learn about the mechanisms that may lead to SLT
- To understand the diagnostic criteria SLT
- To discuss the prevention and treatment options for SLT
- Interventional cardiologists with focus on TAVR procedures
- Cardiac Imaging specialists (Echocardiography, Computer Tomography)
- General cardiologists
- Specialists interested in management of antithrombotic therapies after TAVR
More from this programme
Subclinical leaflet thrombosis after TAVR: Numbers and facts
Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis
Dr Jolanta Siller-Matula is an Associate Professor in the Department of Cardiology at the Medical University of Vienna, Austria. She is an interventional cardiologist specialising in coronary and structural cardiac interventions. She is an expert in thrombosis research with a focus on personalized antithrombotic therapies and authored more than 125 peer-reviewed articles (>4500 citations; h-index: 38). Dr Jolanta Siller-Matula is a leader of a clinical research group with a current focus on stratified approaches aiming at optimizing outcomes after PCI and TAVR.